- Home
- MUE vs EDIT Comparison
MUE vs EDIT Comparison
Compare MUE & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUE | EDIT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.2M | 202.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MUE | EDIT |
|---|---|---|
| Price | $10.17 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 62.6K | ★ 1.9M |
| Earning Date | 01-01-0001 | 03-04-2026 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.53 | $0.91 |
| 52 Week High | $10.17 | $4.54 |
Technical Indicators
Market Signals| Indicator | MUE | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 65.52 | 39.21 |
| Support Level | $9.96 | $1.99 |
| Resistance Level | $10.21 | $2.28 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.76 | 23.08 |
Price Performance
Historical ComparisonAbout MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The Trust seeks to achieve its investment objective by investing principally in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes. Under normal market conditions, the Trust invests at least 80% of its assets in municipal obligations with remaining maturities of one year or more at the time of investment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.